CORDRAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CORDRAN (CORDRAN).
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Primarily hepatic; metabolized via CYP3A4; renal excretion of metabolites. |
| Excretion | Primarily hepatic metabolism; metabolites excreted in urine and feces. Renal excretion of unchanged drug is negligible (<5%). Biliary/fecal excretion accounts for ~20% of metabolites. |
| Half-life | Terminal half-life is approximately 7.5 hours (range 6-10 hours) in adults with normal hepatic function. This supports twined-daily dosing for dermatological indications. |
| Protein binding | Approximately 90% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Apparent volume of distribution is approximately 0.6 L/kg, indicating distribution into total body water and some tissue binding. |
| Bioavailability | Topical: Bioavailability is minimal (<5% systemic absorption) through intact skin. Higher absorption occurs with occluded or damaged skin. No oral bioavailability data; drug is not administered orally. |
| Onset of Action | Topical: Onset of anti-inflammatory effect is within 2-3 hours after application. Systemic effects delayed. |
| Duration of Action | Topical: Duration of clinical effect is 6-8 hours after a single application, requiring twice-daily application for continuous control of inflammation. |
Apply a thin layer to the affected skin areas once or twice daily. For CORDRAN Tape, apply tape to affected area once every 12 to 24 hours.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Apply a thin layer to affected area once or twice daily; use smallest amount effective and limit duration to avoid systemic effects. |
| Geriatric use | Use with caution; apply smallest amount for shortest duration due to increased risk of skin atrophy and systemic absorption. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CORDRAN (CORDRAN).
| Breastfeeding | Topical corticosteroids may be absorbed in small amounts and excreted in breast milk. M/P ratio not available. Use with caution; avoid application to breast area to minimize infant exposure. Risk to nursing infant is likely low with short-term, low-potency use. |
| Teratogenic Risk | Corticosteroids, including CORDRAN (flurandrenolide), are generally considered to have low teratogenic risk when used topically. Systemic exposure is minimal with topical application. Animal studies have shown some risk with systemic corticosteroids, but no controlled human data exist. FDA Pregnancy Category C. First trimester: No increased risk of major malformations reported with topical use. Second and third trimesters: Possible risk of fetal growth restriction with prolonged or high-dose systemic use; topical use not associated. Overall, risk likely low. |
■ FDA Black Box Warning
No FDA boxed warnings.
| Serious Effects |
["Hypersensitivity to any component","Untreated bacterial, fungal, or viral skin infections"]
| Precautions | ["Systemic absorption may cause reversible HPA axis suppression","Local irritation or sensitization","Pediatric patients may have increased susceptibility to systemic effects","Prolonged use may cause skin atrophy or striae"] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required for topical use. For prolonged or extensive use, monitor for maternal adrenal suppression and fetal growth via ultrasound if concerns. |
| Fertility Effects | No known adverse effects on fertility with topical use. Systemic high-dose corticosteroids may impair fertility, but topical flurandrenolide is unlikely to have such effects. |